We reasoned that if stroma-derived vimentin serves as an antigen recognized by CLL cells, it is necessary that vimentin is at least partially expressed on the surface of and/or secreted and/or shed by stromal cells. The gene discussed is VIM; the disease is B-cell chronic lymphocytic leukemia.